Nasdaq Stockholm Welcomes AroCell to First North


Stockholm, June 30, 2016 — Nasdaq (Nasdaq: NDAQ) announces that the trading in AroCell AB’s shares (short name: AROC) commenced today on Nasdaq First North in Stockholm. AroCell belongs to the Health Care sector and is the 50th company to be admitted to trading on Nasdaq’s Nordic markets* in 2016.

AroCell is a Swedish company specialized in developing standardized blood tests that can be used in the prognosis, monitoring and follow-up of cancer. The company’s technology is based on patented methods to measure TK1 protein levels, and the test results provide information that allows oncologists to indirectly monitor tumour growth during cancer treatments. AroCell was founded in 2003 and is headquartered in Uppsala, Sweden. For more information, please visit www.arocell.com .

“The assessment of the Management and Board of Directors is that Nasdaq First North is a market place that will provide a broader exposure of the company to more groups of investors and institutions,” said Jan Stålemark, CEO of AroCell. “In addition, this listing will provide foreign investors with better opportunities to trade in the company’s shares, due to the more international profile and accessibility of Nasdaq First North.”

“We welcome AroCell to Nasdaq First North,” said Adam Kostyál, senior vice president and head of European listings at Nasdaq. “AroCell is yet another example of an innovative health care company leveraging Nasdaq First North as a platform for its future expansion, and we look forward to supporting the company for many years to come.”

AroCell AB has appointed Redeye AB as the Certified Adviser.

*Main markets and Nasdaq First North at Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm.

About Nasdaq First North

Nasdaq First North is regulated as a multilateral trading facility, operated by the different exchanges within Nasdaq Nordic (Nasdaq First North Denmark is regulated as an alternative marketplace). It does not have the legal status as an EU-regulated market. Companies at Nasdaq First North are subject to the rules of Nasdaq First North and not the legal requirements for admission to trading on a regulated market. The risk in such an investment may be higher than on the main market.

About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of over $9.3 trillion and nearly 17,000 corporate clients. To learn more, visit nasdaq.com/ambition or business.nasdaq.com.

Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland, Nasdaq Riga, Nasdaq Stockholm, Nasdaq Tallinn, Nasdaq Vilnius, Nasdaq Clearing and Nasdaq Broker Services are respectively brand names for the regulated markets of Nasdaq Copenhagen A/S, Nasdaq Helsinki Ltd., Nasdaq Iceland hf., Nasdaq Riga, AS, Nasdaq Stockholm AB, Nasdaq Tallinn AS, AB Nasdaq Vilnius, Nasdaq Clearing AB and Nasdaq Broker Services AB. Nasdaq Nordic represents the common offering by Nasdaq Copenhagen, Nasdaq Helsinki, Nasdaq Iceland and Nasdaq Stockholm. Nasdaq Baltic represents the common offering by Nasdaq Tallinn, Nasdaq Riga and Nasdaq Vilnius.

Cautionary Note Regarding Forward-Looking Statements

The matters described herein contain forward-looking statements that are made under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about Nasdaq and its products and offerings. We caution that these statements are not guarantees of future performance. Actual results may differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These factors include, but are not limited to factors detailed in Nasdaq's annual report on Form 10-K, and periodic reports filed with the U.S. Securities and Exchange Commission. We undertake no obligation to release any revisions to any forward-looking statements.

Media Relations Contact:
Erik Granström
+46 8 405 78 07
erik.granstrom@nasdaq.com
 

 


Attachments

20160630_AroCell_bell.jpg